Cumberland Pharmaceuticals (CPIX) Total Non-Current Liabilities (2010 - 2026)

Cumberland Pharmaceuticals (CPIX) has 17 years of Total Non-Current Liabilities data on file, last reported at $44.1 million in Q1 2026.

• For the quarter ending Q1 2026, Total Non-Current Liabilities rose 23.84% year-over-year to $44.1 million; the trailing twelve-month figure through Mar 2026 stood at $44.1 million (up 23.84% YoY), and the FY2025 full-year result was $46.5 million, down 0.6% from the prior year.
• Total Non-Current Liabilities retreated to $44.1 million in Q1 2026, from $46.5 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $49.4 million in Q4 2022 to a low of $33.9 million in Q2 2025.
• A 5-year average of $43.8 million and a median of $45.6 million in 2023 frame the typical range for Total Non-Current Liabilities.
• Across the five-year window, Total Non-Current Liabilities soared 43.64% in 2022 and decreased 26.16% in 2025, its largest moves.
• Tracing CPIX's Total Non-Current Liabilities over 5 years: stood at $49.4 million in 2022, then fell by 6.69% to $46.1 million in 2023, then climbed by 1.47% to $46.7 million in 2024, then dropped by 0.6% to $46.5 million in 2025, then slipped by 5.13% to $44.1 million in 2026.
• Business Quant data shows CPIX's Total Non-Current Liabilities at $44.1 million in Q1 2026, $46.5 million in Q4 2025, and $34.1 million in Q3 2025.